PLRX (Pliant Therapeutics) Short Percentage of Float


PLRX Pliant Therapeutics Inc PLRX
31 GF Score
Price $1.13
! 2 Warning Signs
View Full Analysis

What is Pliant Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

PLRX vs RLYB, LIXT, CSBR: Short Percentage of Float Comparison

For the Biotechnology subindustry, Pliant Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pliant Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pliant Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Pliant Therapeutics's Short Percentage of Float falls into.


PLRX
31GF Score
Pliant Therapeutics Inc PLRX
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pliant Therapeutics Business Description

Other Exchanges 9PT:Germany
Address 331 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
31GF Score

Get the complete analysis for PLRX

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.13
Price